Aortic Regurgitation: Clinical Trials

3 trials for Aortic Regurgitation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Completed 1, Recruiting 1, Unknown 1

Follow Aortic Regurgitation: new trials by email Literature Review of Aortic Regurgitation trials Research Report on Aortic Regurgitation

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System
VitaFlow+GDMT, J-Valve+GDMT - AORTIC VALVE DISEASES, Aortic Regurgitation
Phase 4RecruitingRuijin Hospital1202025-04-292026-01-30
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
Amlodipine 5mg, Losartan, Losartan and Amlodipine - Aortic Stenosis, Aortic Regurgitation
Phase 4CompletedHanmi Pharmaceutical Company Limited1282018-10-182022-09-15
Rivaroxaban or Aspirin for Biological Aortic Prosthesis
Rivaroxaban 10 MG, Aspirin - Aortic Stenosis, Aortic Regurgitation
Phase 4UnknownChristian Torp-Pedersen10002017-01-012018-06-27

Narrower conditions

Aortic Valve Insufficiency (3)  ·  Aortic Valve Stenosis (2)  ·  Aortic Valve Disease (1)  ·  Hypertension (1)  ·  Hypertrophy, Left Ventricular (1)  ·  Thrombosis (1)

Broader conditions

Cardiovascular Diseases (3)  ·  Heart Diseases (3)  ·  Heart Valve Diseases (3)  ·  Aortic Valve Disease (2)  ·  Vascular Diseases (2)  ·  Ventricular Outflow Obstruction (2)  ·  Cardiomegaly (1)  ·  Embolism and Thrombosis (1)  ·  Hypertrophy (1)  ·  Pathological Conditions, Anatomical (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Amlodipine (1)  ·  Aspirin (1)  ·  Losartan (1)  ·  Rivaroxaban (1)  ·  Tablets (1)  ·  amlodipine-losartan drug combination (1)

Sponsors

Christian Torp-Pedersen (1)  ·  Hanmi Pharmaceutical Company Limited (1)  ·  Ruijin Hospital (1)

Countries

China (1)  ·  Denmark (1)  ·  South Korea (1)

Top investigators

Duk-Hyun Kang (1)  ·  ZhengBin Zhu, MD. PhD (1)

Results publications

PMID 32905623, PMID 36398903, PMID 38006908, PMID 41739727

NIH funding

2016 (1)